Volume 17, Number 6—June 2011
Methicillin-Resistant Staphylococcus aureus, Samoa, 2007–2008
|No. (%) isolates||Strain†||MLST type||No. (%) PVL-positive isolates||spa type (% of strain)||Antimicrobial drug susceptibility (% of strain)|
|10 (29)||USA300||ST8||9 (90)||t008 (100)||Resistant to ciprofloxacin and erythromycin (80); resistant to ciprofloxacin (20)|
|9 (26)||Queensland clone||ST93||9 (100)||t3949 (56), t202 (44)‡||Resistant only to β-lactams (100)|
|9§ (26)||–||ST1||0||t1853 (78), t6080 (11)¶||Resistant only to β-lactams (89); resistant to erythromycin** (11)|
|4 (12)||Southwest Pacific/ WSPP/Oceania clone||ST30||4 (100)||t019 (100)||Resistant only to β-lactams (100)|
|2 (6)||AK3||ST5||0||t002 (50), t1265 (50)#||Resistant to erythromycin** (50); resistant only to β-lactams (50)|
*MRSA, methicillin-resistant S. aureus; MLST, multilocus sequence typing; PVL, Panton-Valentine leukocidin; WSPP, Western Samoa Phage Pattern.
†International MRSA strain designations, except for AK3, which is a New Zealand designation for a community-associated MRSA strain common in New Zealand.
‡spa type t3949 (11–17–23–17–17–17–16–16–25) is a single-repeat variant of t202 (11–17–23–17–17–16–16–25). The extra repeat is shown in boldface.
§Only 8/9 ST1 MRSA isolates were available for PVL PCR, spa typing, and pulsed-field gel electrophoresis (PFGE) typing. Seven of the 8 isolates had indistinguishable PFGE profiles, and the eighth shared 87% homology.
¶spa type t6080 (07–23–21–17–13–13–34–16–13–33–13) is a single-repeat variant of t1853 (07–23–21–17–13–34–16–13–33–13). The extra repeat is shown in boldface.
#spa type t1265 (26–23–17–34–17–20–17–12–12–12–16) is a variant of t002 (26–23–17–34–17–20–17–12–17–16). The differing repeats are shown in boldface.
**This isolate also had inducible clindamycin resistance.
- Page created: August 03, 2011
- Page last updated: August 03, 2011
- Page last reviewed: August 03, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)